Navigation Links
Nabsys Secures $20 Million Series D Financing to Support Launch of Semiconductor-Based Single-Molecule Platform for Genomic Analysis
Date:3/12/2013

PROVIDENCE, R.I., March 13, 2013 /PRNewswire/ -- Nabsys, Inc., a life sciences company pioneering solid-state, single-molecule positional sequencing with broad applicability in DNA analysis, today announced that the company has closed a $20 million Series D financing to support the commercial launch of the company's positional sequencing system with initial applications in genome assembly and finishing and in analysis of structural variation in genomes. The financing was led by new investor Bay City Capital with participation from existing investors including Point Judith Capital and Stata Venture Partners.

"We're excited to have the opportunity to help bring Nabsys' technology platform to market," said William Gerber , M.D., investment partner with Bay City Capital.  "We're particularly enthusiastic about the near term clinical applications of structural variant analysis.  Structural variants are known to play a significant role in many forms of cancer as well as other diseases, and Nabsys is poised to offer a system that combines superior analytical performance with a simple and fully automated workflow."

Barrett Bready , M.D., president and chief executive officer of Nabsys, added, "We are delighted to welcome Bay City Capital, with its deep experience working with life sciences companies, to our existing investor group.  Nabsys is at an important transition point as we prepare for commercial launch. This Series D financing will enable us to build a commercial organization that will support launch. Also, because of the scalability of our single-molecule, solid-state, electrical detection technology, we will be able to significantly expand our initial assays and commercialize additional research and diagnostic applications."

Initial applications of the system will allow genomic researchers to correctly and quickly assemble the short DNA sequences that are generated by existing DNA sequencing technologies and to analyze structural variation in a high-throughput way. This is made possible by high-speed, high-resolution electronic measurement of DNA molecules that are much longer than those routinely analyzed by existing sequencing technologies. This same type of data will subsequently be used for a variety of clinical applications, including "electronic karyotyping."

About Nabsys
Nabsys is dedicated to enabling advances in life sciences and healthcare through strategic deployment of a novel positional sequencing platform with broad applicability for DNA analysis. The Nabsys platform uses solid-state nanodetectors to analyze single DNA molecules, revealing both location and identity of DNA sequences over long distances. The system is designed to set new standards for accuracy, speed and scalability, offering compelling advantages for the analysis of genome structural variation, genome mapping, and both targeted and whole genome sequencing. Nabsys was the first company to receive a "$1000 Genome" award from the National Human Genome Research Institute of the National Institutes of Health for an electronic approach to sequencing DNA. For more information about Nabsys, please visit www.Nabsys.com.

 

Company Contact:
Barrett Bready , M.D.
President, Chief Executive Officer and Director
Nabsys, Inc.
401-276-9100 Ext. 200
bready@nabsys.com

Media Contact:
Robert Flamm , Ph.D.
Russo Partners
212-845-4226
Robert.flamm@russopartnersllc.com


'/>"/>
SOURCE Nabsys, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
2. Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference
3. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
4. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
5. Roka Bioscience Secures $47.5 Million in Series D Financing
6. Generex Secures Commitments for $3.6M Capital Raise
7. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
8. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
9. Bacterin Secures $25 Million Financing with OrbiMed
10. OncoSec Secures License for Electroporation Intellectual Property from University of South Florida
11. Aviir Diagnostic Laboratories Secures $8 Million In Funding From Silicon Valley Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2019)... ... November 06, 2019 , ... LeadingBiotech ... dialogue, today announces its East/West CEO conference to be held January ... , Kicking off the week of the J.P. Morgan Healthcare Conference and ...
(Date:11/2/2019)... ... October 31, 2019 , ... Join Patrick ... a live webinar on Friday, November 15, 2019 at 1pm EST ... the science of profiling T-cell receptors (TCRs) and B-cell receptors (BCRs), has been ...
(Date:10/29/2019)... ... October 29, 2019 , ... Modality Solutions, a ... cold chain validation workshop at the Biomanufacturing World Summit (BMWS19) Conference, November 11-12, ... The Biomanufacturing World Summit brings together pharmaceutical executives, cutting-edge technology providers, ...
(Date:10/22/2019)... ... October 22, 2019 , ... Enplug , ... Mass Notification System into its digital signage platform. The collaboration brings one of ... possible for users to leverage their existing digital signage networks to quickly disseminate ...
Breaking Biology Technology:
(Date:11/19/2019)... HERCULES, Calif. (PRWEB) , ... November 19, 2019 ... ... for epigenetics research and sample preparation, and Bio-Rad Laboratories, Inc. (NYSE: BIO and ... announced a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) Services, featuring ...
(Date:11/14/2019)... ... 13, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... approved clinical trial for stem cell treatment of knee osteoarthritis . The first treatment ... subsidiary of VetStem Biopharma. , In July of 2019, PSC received FDA approval ...
(Date:11/12/2019)... ... November 12, 2019 , ... The Arnold and ... universities and research institutions for its Instrumentation Grant for Advanced Light-Sheet Microscopy ... million per site for the acquisition of instrumentation, development and maintenance; support for ...
Breaking Biology News(10 mins):